ADC Therapeutics stock gained 4.63 percent as analysts held Hold consensus

Published on 10/04/2026 at 16:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ADC Therapeutics posted USD 19.25 million in Q2 revenue and an adjusted USD 0.11 loss per share on August 13, 2026. Cash reached USD 219.1 million.

ADCT, CH0499880968, Illustration mit AI erstellt.

ADC Therapeutics stock (ISIN CH0499880968) closed at USD 1.13 on the NYSE on October 2, 2026, gaining 4.63 percent from the prior session. The move leaves the biotechnology company with a USD 143.7 million market capitalization and a stock still positioned close to its USD 0.78 to USD 4.98 52-week range.

Q2 revenue reached USD 19.25 million

The latest reported quarter delivered a mixed but measurable operating picture. According to Zacks in its August 13, 2026 report, ADC Therapeutics generated USD 19.25 million of revenue in the quarter ended June 2026, compared with USD 18.84 million a year earlier. Revenue missed the consensus estimate by 4.48 percent, while the adjusted loss of USD 0.11 per share was narrower than the USD 0.19 consensus loss.

The earnings comparison is the sharper point for investors: the adjusted quarterly loss was USD 0.08 per share smaller than expected, producing a 42.11 percent positive earnings surprise according to Zacks. The finance statement for Q2 2026 puts consolidated net loss at USD 16.565 million and cash and cash equivalents at USD 219.107 million as of June 30, 2026.

Hold consensus contrasts with target

Analyst expectations remain more constructive than the share price, but the rating mix is not uniformly bullish. MarketBeat reported on September 12, 2026 that six brokerages had a Hold consensus, with three Buy ratings, two Hold ratings and one Sell rating. The average 12-month price target was USD 5.00.

Against the October 2 closing price of USD 1.13, that consensus target lies 342.48 percent above the price. The gap reflects the market's low valuation of ADC Therapeutics, but it also leaves the stock sensitive to clinical and regulatory execution around ZYNLONTA.

ZYNLONTA carries the next catalyst

At the September 11, 2026 Cantor Fitzgerald healthcare conference, management presented ZYNLONTA as the commercial base for a broader antibody-drug conjugate strategy. Investing.com reported that the company described annual ZYNLONTA sales of USD 75 million to USD 80 million and a cash runway extending into 2028.

The same conference account highlighted a 78 percent complete response rate among the first 49 patients in LOTIS-7. The counterweight is regulatory risk: the FDA raised benefit-risk concerns about LOTIS-5 after grade 5 treatment-emergent adverse events, primarily infections, according to Investing.com. That safety issue is the central counter-factor to the company's expansion case.

Stock gained on October 2

ADC Therapeutics stock closed at USD 1.13 on the NYSE on October 2, 2026, with 1,310,581 shares traded. The 4.63 percent daily gain came as the stock remained 77.31 percent below its 52-week high of USD 4.98, keeping clinical progress and regulatory clarity central to the valuation discussion.